... A Iniciar en Agosto 2017 por el National Center for Tumor Diseases, Heidelberg con la colaboración de PharmaMar y AstraZeneca .
A Randomized Phase-2 Study of Trabectedin/Olaparib ( Lynparza ) Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies .
Carmem Cuevas Joined PharmaMar in 1997 fulfilling different positions in the R&D Department and was promoted to her current position, Research & Development Director, responsible for the R&D Department at PharmaMar including the areas of Drug Discovery, Medicinal Chemistry, Preclinical and Intellectual Property in 2003. Among other achievements, she is responsible for the development of a totally innovative scaled synthetic process of Yondelis. Carmen Cuevas obtained her PhD in Chemistry by the University of País Vasco, and did her post-doctoral training at the Pharmacology Department of the Faculty of Medicine, University of Alcalá de Henares (Madrid). She is Master Degree (PDD) by IESE. Dr. Cuevas is author of over 100 Scientific International Publications, 30 patent applications, and 65 communications to international Congresses and has participated more than 35 Financed Research Programs.